UB Paderborn / Katalog / Suche / in CDI

1 – 23 von 23

Sortiert nach

Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients

PloS one, 2013-04, Vol.8 (4), p.e62074-e62074

2013

Link zum Volltext

Verfügbarkeit prüfen

Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir

Molecular medicine (Cambridge, Mass.), 2015-04, Vol.21 (1), p.337-345

2015

Link zum Volltext

Verfügbarkeit prüfen

Characteristics of 86 individuals with mpox diagnosed at Copenhagen University Hospital

Danish medical journal, 2023-04, Vol.70 (5)

2023

Link zum Volltext

Verfügbarkeit prüfen

Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients. e62074

PloS one, 2013-04, Vol.8 (4)

2013

Link zum Volltext

Verfügbarkeit prüfen

HIV-1 Reservoirs During Suppressive Therapy

Trends in microbiology (Regular ed.), 2016-05, Vol.24 (5), p.345-355

2016

Link zum Volltext

Verfügbarkeit prüfen

Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals

AIDS (London), 2019-07, Vol.33 (8), p.1315-1325

2019

Link zum Volltext

Verfügbarkeit prüfen

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

The lancet HIV, 2014-10, Vol.1 (1), p.e13-e21

2014

Link zum Volltext

Verfügbarkeit prüfen

Low intraindividual viral evolution is linked to disease progression and need of antiviral treatment initiation in chronic hepatitis B

Journal of hepatology, 2023-06, Vol.78, p.S1050-S1051

2023

Link zum Volltext

Verfügbarkeit prüfen

FRI-271 - Low intraindividual viral evolution is linked to disease progression and need of antiviral treatment initiation in chronic hepatitis B

Journal of hepatology, 2023-06, Vol.78, p.S1050-S1051

2023

Link zum Volltext

Verfügbarkeit prüfen

Broad activation of latent HIV-1 in vivo

Nature communications, 2016-09, Vol.7 (1), p.12731-12731, Article 12731

2016

Link zum Volltext

Verfügbarkeit prüfen

In vitro Characterization of Fitness and Convalescent Antibody Neutralization of SARS-CoV-2 Cluster 5 Variant Emerging in Mink at Danish Farms

Frontiers in microbiology, 2021-06, Vol.12, p.698944-698944

2021

Link zum Volltext

Verfügbarkeit prüfen

HIV-1 Reservoirs During Suppressive Therapy: Special Issue: Microbial Endurance

Trends in microbiology (Regular ed.), 2016-05, Vol.24 (5), p.345-355

2016

Link zum Volltext

Verfügbarkeit prüfen

The Nuc-Stop study: an open-label, randomized trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B patients

JOURNAL OF HEPATOLOGY, 2023, Vol.78, p.S1150-S1151

2023

Link zum Volltext

Verfügbarkeit prüfen

Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment

Journal of clinical virology, 2022-06, Vol.150-151, p.105159-105159, Article 105159

2022

Link zum Volltext

Verfügbarkeit prüfen

SAT-170 - The Nuc-Stop study: an open-label, randomized trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B patients

Journal of hepatology, 2023-06, Vol.78, p.S1150-S1151

2023

Link zum Volltext

Verfügbarkeit prüfen

Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19

EBioMedicine, 2021-09, Vol.71, p.103519-103519, Article 103519

2021

Link zum Volltext

Verfügbarkeit prüfen

Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations

AIDS (London), 2017-03, Vol.31 (6), p.771-779

2017

Link zum Volltext

Verfügbarkeit prüfen

Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination

EBioMedicine, 2023-03, Vol.89, p.104475-104475, Article 104475

2023

Link zum Volltext

Verfügbarkeit prüfen

Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals

AIDS (London), 2018-08, Vol.32 (13), p.1793-1802

2018

Link zum Volltext

Verfügbarkeit prüfen

Romidepsin-induced HIV-1 viremia during effective ART contains identical viral sequences with few deleterious mutations

AIDS (London), 2017-01

2017

Link zum Volltext

Verfügbarkeit prüfen

Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials

Human vaccines & immunotherapeutics, 2013-04, Vol.9 (4), p.790-799

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(22)
Tagungsberichte
(1)

Sprache

Englisch
(23)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients

Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir

Characteristics of 86 individuals with mpox diagnosed at Copenhagen University Hospital

Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients. e62074

HIV-1 Reservoirs During Suppressive Therapy

Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

Low intraindividual viral evolution is linked to disease progression and need of antiviral treatment initiation in chronic hepatitis B

FRI-271 - Low intraindividual viral evolution is linked to disease progression and need of antiviral treatment initiation in chronic hepatitis B

Broad activation of latent HIV-1 in vivo

In vitro Characterization of Fitness and Convalescent Antibody Neutralization of SARS-CoV-2 Cluster 5 Variant Emerging in Mink at Danish Farms

HIV-1 Reservoirs During Suppressive Therapy: Special Issue: Microbial Endurance

The Nuc-Stop study: an open-label, randomized trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B patients

Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment

SAT-170 - The Nuc-Stop study: an open-label, randomized trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B patients

Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19

Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations

Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNA-mRNA or Vector-mRNA COVID-19 Vaccines

Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination

Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals

Romidepsin-induced HIV-1 viremia during effective ART contains identical viral sequences with few deleterious mutations

Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccinationResearch in context

Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials

Suchergebnisse filtern